The use of the last generation insulin analogues for the control of diabetes mellitus in real clinical practice


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

This article discusses the clinical case of managing a patient with type 1 diabetes mellitus, initially treated with multiple injections of first-generation insulin analogues. On this therapy, disease control was unsatisfactory. There were episodes of postprandial hypoglycemia 3 hours after eating. HbAlc level - 8.2%; the patient was 54% of the time in the target glycemic range, 3% of the time - in the hypoglycemic range, and 43% of the time - in the hyperglycemic range. After switching to the last generation insulin analogue (superfast-acting insulin aspart), it was possible to avoid episodes of postprandial hypoglycemia. Subsequently, episodes of nocturnal hypoglycemia occurred, which were managed by switching the patient from two injections of a first-generation basal insulin analogue to one injection of a last-gen-eration basal insulin analogue (degludec). The combined use of the last generation analogues made it possible to achieve normoglycemia without episodes of hypoglycemia (HbAlc - 6.3%, time spent in the target range - 71%, time spent in the hypoglycemic range - 0%).

Толық мәтін

Рұқсат жабық

Авторлар туралы

Olga Koteshkova

Endocrinological Dispensary of the Moscow Healthcare Department

Email: koaia58@mail.ru
Cand. Sci. (Med.), Head of the Department of Education and Treatment of Diabetes

O. Dukhareva

Endocrinological Dispensary of the Moscow Healthcare Department

N. Demidov

Hospital in Moskovsky town of the Moscow Healthcare Department

M. Antsiferov

Endocrinological Dispensary of the Moscow Healthcare Department

Әдебиет тізімі

  1. Nathan, D.M. Realising the long-term promise of insulin therapy: the DCCT/EDIC study. Diabetologia. 2021;64:1049-58. Doi: 10.1007/ S00125-021-05397-4.
  2. Danne T., Nimri R., Battelino T., et al.International Consensus on Use of Continuous Glucose Monitoring. Diabetes Care. 2017;40:1631-40. doi: 10.2337/dc17-1600.
  3. Haahr, H., Heise, T. Fast-Acting Insulin Aspart: A Review of its Pharmacokinetic and Pharmacodynamic Properties and the Clinical Consequences. Clin Pharmacokinet. 2020;59:155-72. doi: 10.1007/s40262-019-00834-5.
  4. International Diabetes Federation Guideline Development Group. Guideline for management of postmeal glucose in diabetes. Diabetes Res Clin Pract. 2014;103(2):256-68. Doi: 10.1016/j. diabres.2012.08.002.
  5. Mathieu C., Bode B.W., Franek E., et al. Efficacy and safety of fast-acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52-week, randomized, treat-to-target, phase III trial. Diabetes Obes Metab. 2018;20(5):1148-55. doi: 10.1111/dom.13205.
  6. Haahr H., Heise T. A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance. Clin Pharmacokinet. 2014;53:787-800. doi: 10.1007/s40262-014-0165-y.
  7. Claxton A.J., Cramer J., Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23(8):1296-310. doi: 10.1016/s0149-2918(01)80109-0.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML

© Bionika Media, 2022

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>